[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL158428A0 - Vaccine composition comprising at least one hiv virus antigen - Google Patents

Vaccine composition comprising at least one hiv virus antigen

Info

Publication number
IL158428A0
IL158428A0 IL15842802A IL15842802A IL158428A0 IL 158428 A0 IL158428 A0 IL 158428A0 IL 15842802 A IL15842802 A IL 15842802A IL 15842802 A IL15842802 A IL 15842802A IL 158428 A0 IL158428 A0 IL 158428A0
Authority
IL
Israel
Prior art keywords
vaccine composition
virus antigen
hiv virus
hiv
antigen
Prior art date
Application number
IL15842802A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of IL158428A0 publication Critical patent/IL158428A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL15842802A 2001-04-27 2002-04-25 Vaccine composition comprising at least one hiv virus antigen IL158428A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0110431A GB0110431D0 (en) 2001-04-27 2001-04-27 Novel compounds
PCT/EP2002/004966 WO2002087614A2 (en) 2001-04-27 2002-04-25 Multivalent vaccine comprising an hiv antigen and an hsv antigen and/or an hpv antigen

Publications (1)

Publication Number Publication Date
IL158428A0 true IL158428A0 (en) 2004-05-12

Family

ID=9913641

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15842802A IL158428A0 (en) 2001-04-27 2002-04-25 Vaccine composition comprising at least one hiv virus antigen

Country Status (20)

Country Link
US (1) US20040131638A1 (xx)
EP (1) EP1381390A2 (xx)
JP (1) JP2004531540A (xx)
KR (1) KR20040030599A (xx)
CN (1) CN1522153A (xx)
AR (1) AR034312A1 (xx)
AU (1) AU2002310802B2 (xx)
BR (1) BR0209161A (xx)
CA (1) CA2445310A1 (xx)
CZ (1) CZ20032942A3 (xx)
GB (1) GB0110431D0 (xx)
HU (1) HUP0303942A3 (xx)
IL (1) IL158428A0 (xx)
MX (1) MXPA03009698A (xx)
MY (1) MY134041A (xx)
NO (1) NO20034695L (xx)
NZ (1) NZ529039A (xx)
PL (1) PL367134A1 (xx)
WO (1) WO2002087614A2 (xx)
ZA (1) ZA200308188B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0405480D0 (en) * 2004-03-11 2004-04-21 Istituto Superiore Di Sanito Novel tat complexes,and vaccines comprising them
GB0413510D0 (en) * 2004-06-16 2004-07-21 Glaxosmithkline Biolog Sa Vaccine
MXPA06014515A (es) * 2004-06-16 2007-03-23 Glaxosmithkline Biolog Sa Vacuna contra vph16 y vph18 y al menos otro tipo de vph seleccionado de vph 31, 45 o 52.
US8778351B2 (en) * 2006-08-30 2014-07-15 University Of Rochester Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
EP2059255A4 (en) 2006-09-08 2011-08-31 Univ Pennsylvania VACCINES AGAINST HSV-1 AND HSV-2 AND METHODS OF USE
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
EP2526966B1 (en) * 2006-12-28 2016-03-23 The Trustees of The University of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US8057804B2 (en) 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US10478490B2 (en) 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
EA027784B1 (ru) * 2008-05-26 2017-09-29 Кадила Хелзкэр Лимитед Комбинированная вакцина против кори и вируса папилломы человека
WO2010074126A1 (ja) * 2008-12-25 2010-07-01 財団法人化学及血清療法研究所 組換え鶏伝染性コリーザワクチン及びその製造方法
KR101911229B1 (ko) 2011-08-19 2018-10-24 임모탈 스피릿 리미티드 항체 및 항체 함유 조성물
BR112017008280A2 (pt) * 2014-10-24 2018-01-02 Hpvvax, Llc. método para o tratamento de um paciente
JP2019506435A (ja) * 2016-02-27 2019-03-07 エイチピーブイヴァックス, リミテッド ライアビリティー カンパニー.Hpvvax, Llc. ワクチンを使用して癌または皮膚病変を治療するための方法および組成物
CN110198736B (zh) * 2016-12-26 2023-12-22 财团法人牧岩生命科学研究所 带状疱疹疫苗组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
DE60043708D1 (de) * 1999-10-13 2010-03-04 Novartis Vaccines & Diagnostic Verfahren zur erhaltung zellimmuneantworten gegen proteinen

Also Published As

Publication number Publication date
CA2445310A1 (en) 2002-11-07
ZA200308188B (en) 2005-01-21
WO2002087614A2 (en) 2002-11-07
NZ529039A (en) 2005-02-25
HUP0303942A3 (en) 2005-11-28
KR20040030599A (ko) 2004-04-09
CN1522153A (zh) 2004-08-18
CZ20032942A3 (cs) 2004-12-15
US20040131638A1 (en) 2004-07-08
NO20034695L (no) 2003-12-03
AU2002310802B2 (en) 2005-03-24
MXPA03009698A (es) 2004-01-29
WO2002087614A3 (en) 2003-04-24
EP1381390A2 (en) 2004-01-21
HUP0303942A2 (hu) 2004-03-01
MY134041A (en) 2007-11-30
NO20034695D0 (no) 2003-10-20
PL367134A1 (en) 2005-02-21
JP2004531540A (ja) 2004-10-14
AR034312A1 (es) 2004-02-18
GB0110431D0 (en) 2001-06-20
BR0209161A (pt) 2004-08-03

Similar Documents

Publication Publication Date Title
IL158428A0 (en) Vaccine composition comprising at least one hiv virus antigen
PL398575A1 (pl) Kompozycja szczepionki przeciwko zakażeniu wirusem Zachodniego Nilu
HK1077601A1 (zh) 針對人免疫缺陷病毒的遺傳疫苗
MXPA03008961A (es) Composicion de vacuna.
HK1067891A1 (en) Influenza vaccine composition
HUS1500047I1 (hu) Rekombináns vakcina West Nile vírus ellen
IL150961A0 (en) Human immunodeficiency virus vaccine
EP1423141A4 (en) VACCINE
GB0121171D0 (en) Vaccine
AU2002307971A1 (en) Vaccine against the nile fever virus
IL157251A0 (en) Hepatitis b virus treatment
GB0001475D0 (en) Virus strains
EP1490396A4 (en) IMMUNOGENIC HIV PEPTIDES AS REAGENTS AND AS VACCINES
IS2797B (is) Bóluefni gegn ISA-veiru
SI1436397T1 (sl) Cepivo proti virusu hepatitisa C
SI1366080T1 (sl) Naravna protitelesa uäśinkovita proti virusu hiv
AU2002314610A1 (en) Attenuated very virulent infectious bursal disease virus
GB0023445D0 (en) Attenuated virus vaccine
AU2002350549A1 (en) Infectious salmon anaemia virus vaccine
GB0100430D0 (en) Virus strains
GB0100288D0 (en) Virus strains
NO20012126D0 (no) HIV-vaksine
GB0125239D0 (en) Malaria vaccine antigen
GB0101138D0 (en) Vaccine composition
AU2002319246A1 (en) White spot syndrome virus vaccine